JO
NGNE icon

John Overdeck’s Neurogene NGNE Stock Holding History

John Overdeck’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,891
Closed -$280K – 5310
2026
Q1 		$280K Buy
13,891
+1,900
+16% +$36.8K ﹤0.01% 4117
2025
Q4 		$247K Sell
11,991
-8,560
-42% -$213K ﹤0.01% 3677
2025
Q3 		$356K Buy
20,551
+54
+0.3% +$1.08K ﹤0.01% 3140
2025
Q2 		$306K Buy
20,497
+9,653
+89% +$151K ﹤0.01% 2784
2025
Q1 		$127K Sell
10,844
-9,785
-47% -$170K ﹤0.01% 2933
2024
Q4 		$472K Buy
+20,629
New +$768K ﹤0.01% 2566
2024
Q2 		– Sell
-3,961
Closed -$202K – 3222
2024
Q1 		$202K Buy
+3,961
New +$132K ﹤0.01% 2716
2023
Q4 		– Sell
-8,552
Closed -$135K – 3298
2023
Q3 		$135K Sell
8,552
-2,008
-19% -$29.6K ﹤0.01% 2711
2023
Q2 		$175K Sell
10,560
-775
-7% -$12.7K ﹤0.01% 2670
2023
Q1 		$159K Sell
11,335
-3,617
-24% -$42.4K ﹤0.01% 2604
2022
Q4 		$152K Sell
14,952
-2,205
-13% -$22.8K ﹤0.01% 2444
2022
Q3 		$220K Buy
17,157
+1,533
+10% +$31.3K ﹤0.01% 2078
2022
Q2 		$322K Buy
15,624
+3,425
+28% +$83.5K ﹤0.01% 2003
2022
Q1 		$459K Buy
12,199
+4,404
+56% +$257K ﹤0.01% 2061
2021
Q4 		$751K Buy
7,795
+1,784
+30% +$217K ﹤0.01% 2828
2021
Q3 		$869K Buy
6,011
+4,056
+207% +$621K ﹤0.01% 2736
2021
Q2 		$361K Buy
1,955
+1,211
+163% +$268K ﹤0.01% 3356
2021
Q1 		$183K Sell
744
-7,693
-91% -$1.97M ﹤0.01% 3645
2020
Q4 		$2.38M Buy
8,437
+1,120
+15% +$274K 0.01% 1385
2020
Q3 		$1.76M Buy
7,317
+2,807
+62% +$680K 0.01% 1381
2020
Q2 		$1.5M Buy
4,510
+2,576
+133% +$671K 0.01% 1261
2020
Q1 		$440K Buy
1,934
+1,249
+182% +$257K ﹤0.01% 2033
2019
Q4 		$169K Sell
685
-2,633
-79% -$262K ﹤0.01% 3461
2019
Q3 		$189K Sell
3,318
-1,287
-28% -$78.5K ﹤0.01% 3206
2019
Q2 		$217K Sell
4,605
-1,490
-24% -$76.6K ﹤0.01% 3048
2019
Q1 		$329K Sell
6,095
-576
-9% -$29.1K ﹤0.01% 2537
2018
Q4 		$288K Sell
6,671
-735
-10% -$35.8K ﹤0.01% 2480
2018
Q3 		$434K Buy
+7,406
New +$437K ﹤0.01% 2557

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

John Overdeck's NGNE Position: Q2 2026 in Review

John Overdeck sold out of Neurogene (NGNE) in Q2 2026, closing a stake of 13,891 shares — an estimated $280K sold.

John Overdeck first reported a position in NGNE in Q3 2018 and held it in 28 quarters. The position peaked at $2.38M in Q4 2020. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • John Overdeck reported no remaining Neurogene position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 13,891 Neurogene shares in Q2 2026, an estimated $280K.
  • John Overdeck first reported a position in Neurogene in Q3 2018 and held it in 28 quarters.
  • John Overdeck's Neurogene position peaked at $2.38M in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.